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Immune checkpoint inhibitors (ICI) have improved the 
prognosis and redefined the treatment strategy of metastatic 
non-small cell lung cancer (NSCLC) patients. In the first-
line setting, ICI have become standard of care (SoC) 
either as monotherapy (pembrolizumab for tumours with 
high programmed cell death ligand-1 (PD-L1) expression 
(≥50%) in Europe or with PD-L1 ≥1% in the United 
States of America) (1-3) regardless of histologic subtype, 
or in combination with chemotherapy regardless of PD-L1 
expression in non-squamous (pembrolizumab/atezolizumab 
plus platinum-doublet chemotherapy, or atezolizumab-
carboplatin-paclitaxel-bevacizumab) (4-7). In contrast to 
non-squamous histology where personalised treatment 
approaches along with ICI have improved the outcome 
(2,4,8), survival improvements in squamous NSCLC have 
been quite limited or without any meaningful clinical 
impact so far (9). However, based on the KEYNOTE-407 
trial, the introduction of ICI in the first-line treatment of 
metastatic squamous NSCLC has marked a step forward 
in the therapeutic strategy of this patient population, 
improving both the outcome (1,2,10) and quality of life 
(11,12). 
The phase III, placebo-controlled, KEYNOTE-407 
trial assessed the progression free survival (PFS), assessed 
by independent radiological review, and overall survival 
(OS) benefit of adding pembrolizumab to carboplatin plus 
(nab)-paclitaxel in 559 treatment-naive metastatic squamous 
NSCLC patients. In case of no disease progression after 
four cycles of the combination strategy, maintenance 
treatment either with pembrolizumab or placebo was 
administered for up to 35 cycles. Stratification factors 
included PD-L1 expression (≥1% versus <1%), choice of 
taxane (paclitaxel versus nab-paclitaxel) and geographic 
region (East Asia versus rest of the world). Of note, 
crossover was allowed: 32% of patients in the control arm 
received an ICI at the time of progression, whereas for 
those who discontinued treatment for any reason the cross-
over percentage reached 43%. 
Baseline characteristics were well balanced between 
the two groups (median age 65 years, approximately 80% 
male, approximately 2/3 Eastern Cooperative Oncology 
Group Performance Status (ECOG PS) 1, majority 
current or former smoker, approximately 2/3 PD-L1 
expression ≥1%). Pembrolizumab compared to placebo 
significantly improved both co-primary endpoints: the OS 
(15.9 versus 11.3 months (HR 0.64, 95% CI: 0.49–0.85, 
P<0.001) and the PFS (6.4 versus 4.8 months, HR 0.56, 
95% CI: 0.45–0.70, P<0.001) (10). In a secondary interim 
analysis, after a median follow-up of 14.3 months, the OS 
benefit with pembrolizumab was maintained (17.1 versus 
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11.6 months HR 0.71, 95% CI: 0.58–0.88), and median 
PFS2 was also longer in the pembrolizumab arm 
(13.8 versus 9.1 months) (13). Interestingly, this outcome 
benefit with pembrolizumab was also observed in the overall 
response rate (57.9% versus 38.4%). Furthermore, the 
addition of pembrolizumab did not increase the percentage 
of grade 3 adverse events (AE’s) compared to chemotherapy 
(69.8% versus 68.2%) or deaths (8.3% versus 6.4%) and had 
no detrimental effect on quality of life (10,12). However, 
percentage of treatment discontinuations was higher in the 
pembrolizumab arm (23.4% versus 11.8%) (10). Based on 
these results, both FDA and EMA approved pembrolizumab 
in combination with chemotherapy in the first-line setting 
on October 30, 2018 and January 31, 2019, respectively. 
As with most ICI trials, clinically stable patients with 
radiological disease progression could continue treatment 
till the next confirmed radiological progression. PFS and 
OS were co-primary endpoints thus being equally powered 
at both the second interim analysis and at the final analysis. 
Furthermore, the interim analyses were performed at 
a database maturity that could allow early data release. 
PD-L1 status, taxane choice and geographic region were 
stratification factors thus being balanced for the subgroup 
analysis across treatment arms. Of note, PD-L1 testing was 
performed centrally and progressive disease was confirmed 
by blinded independent imaging review.
As a crit ical  note,  both the al lowed number of 
chemotherapy cycles  ( four)  and the se lect ion of 
chemotherapeutic drugs can be discussed. However, it has 
never been proven that six instead of four chemotherapy 
cycles are superior with regards to OS (14). In several 
countries, gemcitabine-platinum doublet is the standard 
of care instead of carboplatin-(nab)paclitaxel, which 
may limit the generalizability of the trial results. Indeed, 
the population enrolled may not reflect the real-life 
squamous NSCLC patients as they were all in good clinical 
conditions, with adequate organ function, relatively young, 
and with a low (about 8%) brain metastases rate. This 
potential selection of the patients enrolled into the trial can 
be stated by the fact that almost 30% of screened patients 
did not meet the in- and exclusion criteria anymore at the 
time of randomization.
Although the KEYNOTE 407 trial enrolled patients 
between August, 2016, and December, 2017, when at least 
four large randomized clinical trials had already reported 
a survival benefit with second-line ICIs, only one third of 
patients in the control arm received ICI at progression. 
Although this percentage might increase with longer follow-
up, a high percentage of patients in the control arm did not 
receive a second line treatment potentially overestimating 
the survival benefit with the combination. A possible 
explanation could be a delayed approval for unblinding a 
cross-over since central confirmation of progression was 
mandatory, which could induce a clinical deterioration not 
allowing to start subsequent treatment strategies. 
Based on the plethora of clinical trials assessing 
ICI in the first-line setting, assessment of the real role 
of the KEYNOTE-407 trial in this scenario merits 
further attention. The KEYNOTE-407 has positioned 
pembrolizumab in combination with (nab)-paclitaxel 
and carboplatin as the new SoC for metastatic squamous 
NSCLC (10,13). This is especially after the negative 
survival results of the IMpower131 trial (atezolizumab plus 
carboplatin and nab-paclitaxel) in the same population (15). 
Although differences in OS between both trials could 
be explained by different efficacy between anti-PD1 and 
anti-PD-L1 in squamous NSCLC, grade 3 AEs were 
similar (69% with the pembrolizumab and 66% with the 
atezolizumab-combination) (10,13,15). However, it should 
be pointed out that between the KEYNOTE-407 and 
IMpower131 differences in median follow-up (14.3 versus 
25.5 months) exist, as well as differences in crossover rate 
(32% versus 43%) and in the proportion of PD-L1 positive 
tumors (63% versus 53%). Furthermore, PD-L1 scoring 
was performed differently [22C3 clone with PD-L1 TPS 
for pembrolizumab, SP142 clone with tumour cell (TC)/
immune cell (IC) scoring for atezolizumab]. All of these 
could be considered for explaining the discordant results in 
OS (10,13,15). 
One more point merits attention. With a median follow-
up of 14.3 months, pembrolizumab plus chemotherapy 
improved PFS regardless of PD-L1 expression, but the 
magnitude of OS benefit according to PD-L1 strata was 
less consistent, with survival improvement in tumours 
with PD-L1 expression between 1% to 49%, but not in 
PD-L1 negative tumours (HR 0.79, 95% CI: 0.56–1.11) 
or in tumours with high PD-L1 expression (HR 0.79, 
95% CI: 0.52–1.21). However, the effects of PD-L1 
expression in OS in the KEYNOTE-407 trial were only 
prespecified exploratory endpoints, lacking statistical power, 
while they were secondary endpoints in the IMpower131 
(10,13). As contrary, in the IMpower131 trial, median 
OS was significantly improved with atezolizumab only in 
the subgroup with high PD-L1 expression (TC3 or IC3, 
HR 0.48; 95% CI: 0.29–0.81), but not in PD-L1 positive 
(TC1/2/3 or IC1/2/3, HR 0.86, 95% CI: 0.67–1.11) or PD-
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L1 negative tumours (TC0 or IC0, HR 0.87; 95% CI: 0.67–
1.13) (15). Therefore, is there any role of ICI-chemotherapy 
in PD-L1 negative squamous lung cancer? A recent pooled 
analysis assessed this strategy in 428 PD-L1 negative 
tumours enrolled in three randomized trials (KEYNOTE-
021G, KEYNOTE-189 and KEYNOTE-407). The 
analysis  reported a  c l inical ly  meaningful  benefi t 
improvement in PFS (HR 0.67; 95% CI: 0.53–0.84) and 
OS (HR 0.56; 95% CI: 0.43–0.73) with pembrolizumab 
plus chemotherapy compared with chemotherapy alone, 
although 42% of patients in the control arm received an 
anti-PD(L)1 at the time of progression. The OS benefit 
was observed in all subgroups, including squamous NSCLC 
(HR 0.61; 95% CI: 0.38–0.96) (16). In the CheckMate227 
trial, part 2, nivolumab plus chemotherapy did not meet 
its primary endpoint of significantly prolonged OS versus 
chemotherapy alone in treatment-naïve non-squamous 
NSCLC (HR 0.86, 95% CI: 0.69–1.08, P=0.186) (17). 
For all randomized patients in the trial as well as in the 
squamous group, nivolumab plus chemotherapy showed 
improved OS (HR 0.81; 95% CI: 0.67–0.92 and HR: 
0.69; 95% CI: 0.50–0.97, respectively) compared with 
chemotherapy. Of note, it was a descriptive analysis and 
outcomes by histology according to PD-L1 expression were 
not reported. However, in all randomized patients, HR for 
OS was similar regardless of PD-L1 expression, not clearly 
supporting PD-L1 expression as a predictive biomarker for 
this combination (17). 
Finally, whether ICI-ICI combination is or is not 
a potential strategy in squamous histology is another 
challenging question. CheckMate227 trial part 1 reported 
a significant survival improvement with nivolumab plus 
ipilimumab compared with chemotherapy alone in PD-
L1 positive NSCLC (HR 0.79, 97.7% CI: 0.65–0.96, 
P=0.007) and the survival benefit occurred regardless 
PD-L1 expression or tumour mutational burden (TMB) 
cut-off. Survival benefit was also reported in squamous 
histological subtype (14.8 versus 9.2 months, HR 0.69, 95% 
CI: 0.52–0.92) (18). Of note, as patients were not stratified 
by PD-L1 ≥ or <50%, subgroup analyses may be impacted 
by imbalances and should be interpreted with caution. The 
role of ICI-ICI in first-line remains controversial, as the 
control arm in the CheckMate227 trial (platinum-based 
chemotherapy) is suboptimal. Moreover, the risk of early 
death/ progression, observed with ICI-ICI combinations 
based on the fact that curves crosses, seems to be averted 
with immune-chemotherapy combinations (10,18). 
Recently, two trials have not reported survival benefit 
with ICI-ICI combination compared with chemotherapy, 
the MYSTIC trial  in PD-L1 ≥25% tumours (19) 
and the NEPTUNE trial (NCT02542293) in high blood 
TMB tumours, further confounding the role of ICI-
ICI combinations in first-line setting. Pending data from 
CheckMate9LA (NCT03215706) may help to clarify the 
role of this strategy. 
As stated above, ICI are the major improvement in this 
patient population in the last ten years. Since more than 
half of the squamous NSCLC patients still do not obtain 
long-term benefit from ICI treatment strategies, more 
data should be obtained on biomarkers as well as patient 
selection for ICI treatment. PD-L1 expression is a valid, 
although imperfect biomarker for ICI efficacy. In high PD-
L1 expression tumours (≥50%), several phase III clinical 
trials have reported significant survival improvements with a 
favourable toxicity profile with anti-PD(L)1 drugs compared 
with platinum-based chemotherapy (2,3,20). However, 
the magnitude of survival benefit with monotherapy is less 
pronounced in squamous histology (2,20), probably due to 
the limited number of patients with squamous histology 
enrolled in these trials. However, these data do not allow 
rejecting monotherapy as a potential strategy in this 
subgroup of NSCLC patients or testing PD-L1 expression 
in squamous lung carcinomas. Indeed in a retrospective 
cohort the magnitude of benefit from pembrolizumab 
monotherapy increased with higher PD-L1 expression, with 
improved RR (60.0% versus 32.7%, P<0.001), and longer 
PFS [14.5 versus 4.1 months, HR 0.50 (95% CI: 0.33–
0.74)], and OS (not reached versus 15.9 months, HR 0.39; 
95% CI: 0.21–070) in tumours with a very high PD-L1 
expression (90–100%) compared with those tumours with 
PD-L1 expression between 50% to 89% (21). However, 
for instance, no trials have compared combination therapy 
versus pembrolizumab monotherapy in the PD-L1 ≥50% 
patient population. Based on the retrospective series, future 
trials should probably stratify for high versus very high 
PD-L1 expression. Finally, the TMB has not been validated 
as predictive biomarker for ICI-chemotherapy combination 
in the KEYNOTE-407 trial (22). 
Importantly, the KEYNOTE-407 included only a low 
percentage of (selected) patients with brain metastases 
(N=44, 8%). Therefore, it is unclear whether this patient 
population also derives benefit from pembrolizumab-
chemotherapy, although a pooled analysis of three 
KEYNOTE trials (021, 189 and 407) suggested benefit 
from pembrolizumab-chemotherapy, compared with 
chemotherapy alone among patients with brain metastases (5). 
822 Hendriks et al. Immune-chemotherapy for squamous NSCLC
  Transl Lung Cancer Res 2020;9(3):819-823 | http://dx.doi.org/10.21037/tlcr.2020.03.36© Translational Lung Cancer Research. All rights reserved.
A patient population that comprises approximately 25% 
of daily practice (23), is the performance status (PS) 
2 group of patients. However, this group was excluded in 
all chemotherapy-ICI trials. Based on ICI monotherapy 
data, these patients do not derive the same benefit as those 
with a PS of 0-1. It is not clear whether ICI-chemotherapy 
combinations are safe and effective in this group. 
Furthermore, new treatment strategies are needed, 
either in first line or upon progression. Combinations with 
radiotherapy are of interest because of the synergy between 
radiation and ICI (24). Especially in oligometastatic but 
also in polymetastatic NSCLC, several trials combining ICI 
and radiation with or without chemotherapy are ongoing 
[e.g., ETOP-CHESS (NCT03965468), NIRVANA-LUNG 
(NCT03774732), IMMUNOSABR2 (NCT03705403), 
NCT03391869, NCT03275597, NCT03509584)]. 
Last, current options in squamous NSCLC patients, 
progressing on chemotherapy-ICI are limited, with docetaxel 
monotherapy being the SoC. Treatment at progression is a 
challenge, and the best next line of treatment is being explored 
in several trials [e.g., NCT03626545, NCT03906071, 
NCT03705403 ,  NCT03406468 ,  NCT02750514 
(FRACTION-lung), NCT03334617 (HUDSON)]. Results of 
these trials are eagerly awaited.
To conclude, the KEYNOTE-407 trial positioned 
pembrolizumab-chemotherapy as the new first line 
treatment of metastatic squamous NSCLC patients with 
a good PS. Future research should focus on biomarkers 
associated with (lack of) long-term ICI benefit, special 
populations such as PS2 and brain metastases, as well as 
new therapeutic strategies upon ICI progression.
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